FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. – Trademark Portfolio

Entity Type: 99

FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 28 (Toys & Sporting Goods) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ARTWILL. The owner is based in FOSHAN CITY.

PLANT A201-B,NO.3 SHANGBAI SHUICHANG

AVE,, LUOCUN, SHISHAN TOWN, NANHAI

FOSHAN CITY 528226 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ARTWILL
ARTWILL
Registered 2020

Trademark Classifications

FOSHAN SHANXING BIOTECHNOLOGY CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

28
Toys & Sporting Goods (1 filing)

Games and playthings; gymnastic and sporting articles; decorations for Christmas trees

Frequently Asked Questions

How many trademarks does FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. have?

FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. file in?

FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 28 (Toys & Sporting Goods). Class 28 covers games and playthings; gymnastic and sporting articles; decorations for christmas trees.

What are FOSHAN SHANXING BIOTECHNOLOGY CO., LTD.'s most well-known trademarks?

FOSHAN SHANXING BIOTECHNOLOGY CO., LTD.'s registered trademark portfolio includes well-known marks such as ARTWILL. These are among 1 currently registered trademark in the portfolio.

What is FOSHAN SHANXING BIOTECHNOLOGY CO., LTD.'s trademark registration success rate?

FOSHAN SHANXING BIOTECHNOLOGY CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.